Anticancer agents against malaria: time to revisit?

dc.contributor.author	Nzila, A
dc.contributor.author	Okombo, J,
dc.contributor.author	Becker, RP
dc.contributor.author	Chilengi, R
dc.contributor.author	Lang, T.
dc.contributor.author	Niehues, T
dc.date.accessioned	2013-06-27T14:20:31Z
dc.date.available	2013-06-27T14:20:31Z
dc.date.issued	2010-03
dc.identifier.citation	Nzila A, Okombo J, Becker RP, Chilengi R, Lang T, Niehues T.;Anticancer agents against malaria: time to revisit?,Trends Parasitol. 2010 Mar;26(3):125-9.	en
dc.identifier.uri	http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/41263
dc.description.abstract	The emergence of artemisinin resistance could adversely impact the current strategy for malaria treatment; thus, new drugs are urgently needed. A possible approach to developing new antimalarials is to find new uses for old drugs. Some anticancer agents such as methotrexate and trimetrexate are active against malaria. However, they are commonly perceived to be toxic and thus not suitable for malaria treatment. In this opinion article, we examine how the toxicity of anticancer agents is just a matter of dose or 'only dose makes the poison', as coined in Paracelsus' law. Thus, the opportunity exists to discover new antimalarials using the anticancer pharmacopoeia.	en
dc.description.uri	http://www.sciencedirect.com/science/article/pii/S1471492209002633
dc.language.iso	en	en
dc.publisher	University of Nairobi,	en
dc.title	Anticancer agents against malaria: time to revisit?	en
dc.type	Article	en
local.publisher	College of Health Sciences,	en